Gastric neoplasm
diseaseOn this page
Also known as gastric tumorgastric tumourneoplasm of stomachneoplasm of the stomachstomach neoplasmstomach neoplasm (disease)stomach tumorstomach tumourtumor of stomachtumor of the stomachtumour of stomachtumour of the stomach
Summary
Gastric neoplasm (MONDO:0021085) is a cancer (an umbrella term covering 6 Mondo subtypes) with 7 cohort genes (5 CIViC-evidence somatic drivers; 69 ClinVar predisposition records) and 365 clinical trials. Top therapeutic interventions include irinotecan, pembrolizumab, and fruquintinib.
At a glance
- Classification: Cancer
- Umbrella term: 6 Mondo subtypes
- Cohort genes: 7
- ClinVar variants: 69
- Clinical trials: 365
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | gastric neoplasm |
| Mondo ID | MONDO:0021085 |
| EFO | EFO:0003897 |
| MeSH | D013274 |
| NCIT | C3387 |
| SNOMED CT | 126824007 |
| UMLS | C0038356 |
| MedGen | 20958 |
| Anatomy (UBERON) | UBERON:0000945 |
| Is cancer (heuristic) | yes |
Also known as: gastric neoplasm · gastric tumor · gastric tumour · neoplasm of stomach · neoplasm of the stomach · stomach neoplasm · stomach neoplasm (disease) · stomach tumor · stomach tumour · tumor of stomach · tumor of the stomach · tumour of stomach · tumour of the stomach
Data availability: 69 ClinVar variants.
Disease family
An umbrella term covering 6 Mondo subtypes.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › stomach disorder › gastric neoplasm
Related subtypes (18): gastric ulcer, functional gastric disease, Dieulafoy lesion, pylorospasm, cascade stomach, pyloric stenosis, gastric dilatation, stomach diverticulosis, gastritis, gastroesophageal reflux disease, hiatus hernia, stomach polyp, non-hypoproteinemic hypertrophic gastropathy, angiodysplasia of stomach, achlorhydria, gastric intestinal metaplasia, gastric duplication, pyloric duplication
Subtypes (6): gastric cancer, gastric neuroendocrine neoplasm, gastric teratoma, gastric adenoma, gastric hamartomatous polyp, benign neoplasm of stomach
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
69 retrieved; paginated sample, class counts are floors:
27 conflicting classifications of pathogenicity, 15 uncertain significance, 11 pathogenic, 10 pathogenic/likely pathogenic, 3 benign, 2 likely benign, 1 likely pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 127312 | NM_000038.6(APC):c.646C>T (p.Arg216Ter) | APC | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 140952 | NM_000038.6(APC):c.637C>T (p.Arg213Ter) | APC | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 184999 | NM_000038.6(APC):c.847C>T (p.Arg283Ter) | APC | Pathogenic | reviewed by expert panel |
| 217924 | NM_000038.6(APC):c.1312+3A>G | APC | Pathogenic | reviewed by expert panel |
| 233970 | NM_000038.6(APC):c.933+1G>A | APC | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 42248 | NM_000038.6(APC):c.694C>T (p.Arg232Ter) | APC | Pathogenic | reviewed by expert panel |
| 545962 | NM_000038.6(APC):c.3867T>A (p.Cys1289Ter) | APC | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 807 | NM_000038.6(APC):c.1660C>T (p.Arg554Ter) | APC | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 810 | NM_000038.6(APC):c.2805C>A (p.Tyr935Ter) | APC | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 13263 | NM_000141.5(FGFR2):c.1025G>A (p.Cys342Tyr) | FGFR2 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 13268 | NM_000141.5(FGFR2):c.1032G>A (p.Ala344=) | FGFR2 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 13273 | NM_000141.5(FGFR2):c.758C>G (p.Pro253Arg) | FGFR2 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 13277 | NM_000141.5(FGFR2):c.1124A>G (p.Tyr375Cys) | FGFR2 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 374817 | NM_000141.5(FGFR2):c.1013G>A (p.Gly338Glu) | FGFR2 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 449024 | NM_000141.5(FGFR2):c.314A>G (p.Tyr105Cys) | FGFR2 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 478046 | NM_000141.5(FGFR2):c.1150G>A (p.Gly384Arg) | FGFR2 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 127845 | NM_001048174.2(MUTYH):c.13C>T (p.Arg5Ter) | MUTYH | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 140877 | NM_001048174.2(MUTYH):c.650G>A (p.Arg217His) | MUTYH | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 234229 | NM_001048174.2(MUTYH):c.305-1G>C | MUTYH | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 5294 | NM_001048174.2(MUTYH):c.1103G>A (p.Gly368Asp) | MUTYH | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 39705 | NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) | PIK3CA | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 417906 | NM_001048174.2(MUTYH):c.1145_1146dup (p.Pro383fs) | MUTYH | Likely pathogenic | no assertion criteria provided |
| 135709 | NM_000038.6(APC):c.5801C>T (p.Pro1934Leu) | APC | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 141436 | NM_000038.6(APC):c.8389A>G (p.Ser2797Gly) | APC | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 141618 | NM_000038.6(APC):c.6639G>A (p.Met2213Ile) | APC | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 141690 | NM_000038.6(APC):c.8276G>A (p.Arg2759His) | APC | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 184169 | NM_000038.6(APC):c.5105G>A (p.Gly1702Glu) | APC | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 216151 | NM_000038.6(APC):c.1606G>A (p.Glu536Lys) | APC | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 216188 | NM_000038.6(APC):c.8462A>G (p.Asp2821Gly) | APC | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 218010 | NM_000038.6(APC):c.95A>G (p.Asn32Ser) | APC | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 60 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Somatic driver evidence (intOGen + CIViC, cohort fanout)
| Gene | intOGen role | Cancer types | CIViC |
|---|---|---|---|
| TP53 | LoF | ACC,ALL,AML,ANGS,ANSC,BCC,BL,BLADDER,BLCA,BRCA,CCRCC,CEAD,CESC,CHOL,CHRCC,CLLSLL,COAD,COADREAD,CSCC,DLBCLNOS,EGC,ES,ESCA,ESCC,GB,GBC,GBM,GIST,HCC,HGGNOS,HNSC,LGGNOS,LIPO,LMS,LNM,LUAD,LUSC,MBL,MEL,MLYM,MT,NBL,NETNOS,NHL,NPC,NSCLC,OS,OVT,PAAD,PANCREAS,PAST,PCM,PLMESO,PRAD,PRCC,PROSTATE,RCC,READ,SACA,SARCNOS,SCLC,SIC,SKCM,SKIN,SOFT_TISSUE,STAD,STOMACH,THYM,UCEC,UCS,UTUC,VULVA,WDTC,WT | CIViC #45 |
| CDH1 | LoF | BLCA,BRCA,CSCC,DLBCLNOS,ESCA,STAD | CIViC #888 |
| FGFR2 | Act | BRCA,CHOL,LUSC,SACA,UCEC | CIViC #22 |
| APC | LoF | AML,ANSC,CHOL,COAD,COADREAD,CSCC,EGC,ESCA,ESCC,HCC,LUAD,MEL,MT,NETNOS,NSCLC,PRAD,PROSTATE,READ,STAD,STOMACH,UM,VULVA | CIViC #66 |
| PIK3CA | Act | ACYC,ANGS,ANSC,BCC,BLADDER,BLCA,BRCA,CCRCC,CEAD,CESC,CHOL,COAD,COADREAD,EPM,ESCA,ESCC,GB,GBM,HCC,HGGNOS,HNSC,LGGNOS,LIPO,LMS,LUAD,LUSC,MBL,MGCT,NPC,NSCLC,OVT,PAAD,PAST,PLMESO,PRAD,PRCC,PROSTATE,RCC,SACA,SKCM,SOFT_TISSUE,STAD,UCEC,UCS,UTUC,VULVA,WDTC | CIViC #37 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| TP53 | Orphanet:1333 | Familial pancreatic carcinoma |
| TP53 | Orphanet:145 | Hereditary breast and/or ovarian cancer syndrome |
| TP53 | Orphanet:1501 | Adrenocortical carcinoma |
| TP53 | Orphanet:210159 | Adult hepatocellular carcinoma |
| TP53 | Orphanet:251576 | Gliosarcoma |
| TP53 | Orphanet:251579 | Giant cell glioblastoma |
| TP53 | Orphanet:251899 | Choroid plexus carcinoma |
| TP53 | Orphanet:2807 | Papilloma of choroid plexus |
| TP53 | Orphanet:293199 | Pleomorphic rhabdomyosarcoma |
| TP53 | Orphanet:3318 | Essential thrombocythemia |
| TP53 | Orphanet:524 | Li-Fraumeni syndrome |
| TP53 | Orphanet:52688 | Myelodysplastic syndrome |
| TP53 | Orphanet:585909 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) |
| TP53 | Orphanet:667662 | Breast implant-associated anaplastic large cell lymphoma |
| TP53 | Orphanet:668 | Osteosarcoma |
| TP53 | Orphanet:67038 | B-cell chronic lymphocytic leukemia |
| TP53 | Orphanet:70573 | Small cell lung cancer |
| TP53 | Orphanet:96253 | Cushing disease |
| TP53 | Orphanet:99756 | Alveolar rhabdomyosarcoma |
| TP53 | Orphanet:99757 | Embryonal rhabdomyosarcoma |
| CASP10 | Orphanet:3261 | Autoimmune lymphoproliferative syndrome |
| CDH1 | Orphanet:1331 | Familial prostate cancer |
| CDH1 | Orphanet:199306 | Cleft lip/palate |
| CDH1 | Orphanet:1997 | Blepharo-cheilo-odontic syndrome |
| CDH1 | Orphanet:227535 | Hereditary breast cancer |
| CDH1 | Orphanet:26106 | Hereditary diffuse gastric cancer |
| FGFR2 | Orphanet:1540 | Jackson-Weiss syndrome |
| FGFR2 | Orphanet:1555 | Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome |
| FGFR2 | Orphanet:168624 | Familial scaphocephaly syndrome, McGillivray type |
| FGFR2 | Orphanet:207 | Crouzon syndrome |
| FGFR2 | Orphanet:2363 | Lacrimoauriculodentodigital syndrome |
| FGFR2 | Orphanet:313855 | FGFR2-related bent bone dysplasia |
| FGFR2 | Orphanet:596008 | Antley-Bixler syndrome without genital anomaly or disorder of steroidogenesis |
| FGFR2 | Orphanet:794 | Saethre-Chotzen syndrome |
| FGFR2 | Orphanet:87 | Apert syndrome |
| FGFR2 | Orphanet:93258 | Pfeiffer syndrome type 1 |
| FGFR2 | Orphanet:93259 | Pfeiffer syndrome type 2 |
| FGFR2 | Orphanet:93260 | Pfeiffer syndrome type 3 |
| APC | Orphanet:220460 | Attenuated familial adenomatous polyposis |
| APC | Orphanet:261584 | 5q22 microdeletion syndrome |
| APC | Orphanet:314022 | Gastric adenocarcinoma and proximal polyposis of the stomach |
| APC | Orphanet:3258 | Cenani-Lenz syndrome |
| APC | Orphanet:873 | Desmoid tumor |
| MUTYH | Orphanet:247798 | MUTYH-related polyposis |
| MUTYH | Orphanet:440437 | Familial colorectal cancer Type X |
| PIK3CA | Orphanet:140944 | CLOVES syndrome |
| PIK3CA | Orphanet:144 | Lynch syndrome |
| PIK3CA | Orphanet:168984 | CLAPO syndrome |
| PIK3CA | Orphanet:201 | Cowden syndrome |
| PIK3CA | Orphanet:210159 | Adult hepatocellular carcinoma |
Cohort genes → proteins
7 cohort genes, 7 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 7 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| TP53 | HGNC:11998 | ENSG00000141510 | P04637 | Cellular tumor antigen p53 | clinvar |
| CASP10 | HGNC:1500 | ENSG00000003400 | Q92851 | Caspase-10 | clinvar |
| CDH1 | HGNC:1748 | ENSG00000039068 | P12830 | Cadherin-1 | clinvar |
| FGFR2 | HGNC:3689 | ENSG00000066468 | P21802 | Fibroblast growth factor receptor 2 | clinvar |
| APC | HGNC:583 | ENSG00000134982 | P25054 | Adenomatous polyposis coli protein | clinvar |
| MUTYH | HGNC:7527 | ENSG00000132781 | Q9UIF7 | Adenine DNA glycosylase | clinvar |
| PIK3CA | HGNC:8975 | ENSG00000121879 | P42336 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| TP53 | Cellular tumor antigen p53 | Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence. |
| CASP10 | Caspase-10 | Involved in the activation cascade of caspases responsible for apoptosis execution. |
| CDH1 | Cadherin-1 | Cadherins are calcium-dependent cell adhesion proteins. |
| FGFR2 | Fibroblast growth factor receptor 2 | Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic de… |
| APC | Adenomatous polyposis coli protein | Tumor suppressor. |
| MUTYH | Adenine DNA glycosylase | Involved in oxidative DNA damage repair. |
| PIK3CA | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. |
Protein-family classification
Druggable: 3 · Difficult: 1 · Unknown: 3 · Druggable fraction: 0.43
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Kinase | 2 | 7.9× | 0.097 |
| Enzyme (other) | 1 | 1.7× | 0.793 |
| Transcription factor | 1 | 1.2× | 0.793 |
| Other/Unknown | 3 | 0.8× | 0.858 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| TP53 | Transcription factor | no | p53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn | |
| CASP10 | Enzyme (other) | yes | 3.4.22.63 | Pept_C14_p20, DED_dom, Pept_C14_p10 |
| CDH1 | Other/Unknown | no | Cadherin_Y-type_LIR, Cadherin-like_dom, Cadherin_pro_dom | |
| FGFR2 | Kinase | yes | 2.7.10.1 | Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Ig_sub2 |
| APC | Other/Unknown | no | Armadillo, APC_rpt, SAMP | |
| MUTYH | Other/Unknown | no | NUDIX_hydrolase_dom, HhH_motif, HhH-GPD_domain | |
| PIK3CA | Kinase | yes | 2.7.1.137 | PI3K_Ras-bd_dom, PI3/4_kinase_cat_dom, PI3K_accessory_dom |
Expression context
Cohort genes with no expression data: 0.
7 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 7 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| ganglionic eminence | 1 |
| tendon of biceps brachii | 1 |
| ventricular zone | 1 |
| colonic epithelium | 1 |
| granulocyte | 1 |
| monocyte | 1 |
| esophagus squamous epithelium | 1 |
| gingival epithelium | 1 |
| jejunal mucosa | 1 |
| C1 segment of cervical spinal cord | 1 |
| corpus callosum | 1 |
| spinal cord | 1 |
| medial globus pallidus | 1 |
| substantia nigra pars compacta | 1 |
| substantia nigra pars reticulata | 1 |
| cerebellar cortex | 1 |
| cerebellar hemisphere | 1 |
| right hemisphere of cerebellum | 1 |
| adrenal tissue | 1 |
| calcaneal tendon | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| TP53 | 223 | ubiquitous | marker | ventricular zone, ganglionic eminence, tendon of biceps brachii |
| CASP10 | 206 | ubiquitous | marker | colonic epithelium, granulocyte, monocyte |
| CDH1 | 245 | broad | marker | jejunal mucosa, esophagus squamous epithelium, gingival epithelium |
| FGFR2 | 272 | broad | marker | C1 segment of cervical spinal cord, spinal cord, corpus callosum |
| APC | 297 | ubiquitous | marker | substantia nigra pars compacta, substantia nigra pars reticulata, medial globus pallidus |
| MUTYH | 134 | ubiquitous | marker | cerebellar hemisphere, cerebellar cortex, right hemisphere of cerebellum |
| PIK3CA | 284 | ubiquitous | marker | calcaneal tendon, adrenal tissue, tendon |
Protein interactions among cohort
Intra-cohort edges: 1.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| TP53 | 22,736 |
| CDH1 | 8,738 |
| PIK3CA | 5,157 |
| APC | 2,903 |
| MUTYH | 1,815 |
| CASP10 | 1,242 |
| FGFR2 | 449 |
Intra-cohort edges
| A | B | Sources |
|---|---|---|
| CASP10 | TP53 | string_interaction |
Structural data
PDB: 6 · AlphaFold-only: 1 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| TP53 | P04637 | 313 |
| PIK3CA | P42336 | 135 |
| FGFR2 | P21802 | 63 |
| APC | P25054 | 31 |
| CDH1 | P12830 | 22 |
| MUTYH | Q9UIF7 | 3 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| CASP10 | Q92851 | 69.54 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 200. Enrichment computed across 7 evidence-associated genes (7 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| TP53 Regulates Transcription of Caspase Activators and Caspases | 2 | 271.9× | 0.004 | TP53, CASP10 |
| PI-3K cascade:FGFR2 | 2 | 141.9× | 0.004 | FGFR2, PIK3CA |
| Apoptotic cleavage of cellular proteins | 2 | 135.9× | 0.004 | CDH1, APC |
| Apoptotic execution phase | 2 | 135.9× | 0.004 | CDH1, APC |
| Ovarian tumor domain proteases | 2 | 79.6× | 0.008 | TP53, APC |
| PI3K Cascade | 2 | 77.7× | 0.008 | FGFR2, PIK3CA |
| Signaling by FGFR2 in disease | 2 | 75.9× | 0.008 | FGFR2, PIK3CA |
| Signaling by FGFR2 amplification mutants | 1 | 1631.4× | 0.009 | FGFR2 |
| APC truncation mutants are not K63 polyubiquitinated | 1 | 1631.4× | 0.009 | APC |
| Signaling by FGFR2 fusions | 1 | 1631.4× | 0.009 | FGFR2 |
| Defective MUTYH substrate binding | 1 | 1631.4× | 0.009 | MUTYH |
| Defective MUTYH substrate processing | 1 | 1631.4× | 0.009 | MUTYH |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | 1 | 1631.4× | 0.009 | TP53 |
| Apoptosis | 2 | 48.0× | 0.010 | CDH1, APC |
| Signaling by ALK fusions and activated point mutants | 2 | 42.9× | 0.012 | TP53, PIK3CA |
| Programmed Cell Death | 2 | 41.8× | 0.012 | CDH1, APC |
| Regulation of TP53 Expression | 1 | 815.7× | 0.014 | TP53 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 2 | 36.2× | 0.014 | FGFR2, PIK3CA |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 2 | 27.6× | 0.023 | FGFR2, PIK3CA |
| Transcriptional activation of cell cycle inhibitor p21 | 1 | 407.9× | 0.024 | TP53 |
| FasL/ CD95L signaling | 1 | 326.3× | 0.025 | CASP10 |
| Activation of NOXA and translocation to mitochondria | 1 | 271.9× | 0.025 | TP53 |
| MET activates PI3K/AKT signaling | 1 | 271.9× | 0.025 | PIK3CA |
| Activated NTRK3 signals through PI3K | 1 | 271.9× | 0.025 | PIK3CA |
| RUNX3 regulates CDKN1A transcription | 1 | 233.1× | 0.025 | TP53 |
| Activated NTRK2 signals through PI3K | 1 | 233.1× | 0.025 | PIK3CA |
| Signaling by LTK in cancer | 1 | 233.1× | 0.025 | PIK3CA |
| TRAIL signaling | 1 | 203.9× | 0.025 | CASP10 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | 1 | 203.9× | 0.025 | CDH1 |
| PI3K/AKT activation | 1 | 181.3× | 0.025 | PIK3CA |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| response to muscle inactivity | 1 | 2407.4× | 0.009 | PIK3CA |
| fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cell | 1 | 2407.4× | 0.009 | FGFR2 |
| fibroblast growth factor receptor signaling pathway involved in hemopoiesis | 1 | 2407.4× | 0.009 | FGFR2 |
| fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow | 1 | 2407.4× | 0.009 | FGFR2 |
| negative regulation of helicase activity | 1 | 2407.4× | 0.009 | TP53 |
| lateral sprouting from an epithelium | 1 | 2407.4× | 0.009 | FGFR2 |
| cellular response to actinomycin D | 1 | 2407.4× | 0.009 | TP53 |
| regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 1 | 2407.4× | 0.009 | TP53 |
| negative regulation of G1 to G0 transition | 1 | 2407.4× | 0.009 | TP53 |
| response to butyrate | 1 | 2407.4× | 0.009 | PIK3CA |
| positive regulation of execution phase of apoptosis | 2 | 240.7× | 0.009 | TP53, CASP10 |
| embryonic organ development | 2 | 137.6× | 0.009 | TP53, FGFR2 |
| positive regulation of neuron apoptotic process | 2 | 77.7× | 0.009 | TP53, CASP10 |
| insulin receptor signaling pathway | 2 | 63.4× | 0.009 | APC, PIK3CA |
| cell migration | 3 | 26.4× | 0.009 | CDH1, APC, PIK3CA |
| orbitofrontal cortex development | 1 | 1203.7× | 0.010 | FGFR2 |
| positive regulation of mitochondrial membrane permeability | 1 | 1203.7× | 0.010 | TP53 |
| prostate gland morphogenesis | 1 | 1203.7× | 0.010 | FGFR2 |
| squamous basal epithelial stem cell differentiation involved in prostate gland acinus development | 1 | 1203.7× | 0.010 | FGFR2 |
| mammary gland bud formation | 1 | 1203.7× | 0.010 | FGFR2 |
| branch elongation involved in salivary gland morphogenesis | 1 | 1203.7× | 0.010 | FGFR2 |
| mesenchymal cell differentiation involved in lung development | 1 | 1203.7× | 0.010 | FGFR2 |
| oligodendrocyte apoptotic process | 1 | 1203.7× | 0.010 | TP53 |
| negative regulation of glucose catabolic process to lactate via pyruvate | 1 | 1203.7× | 0.010 | TP53 |
| negative regulation of pentose-phosphate shunt | 1 | 1203.7× | 0.010 | TP53 |
| obsolete homolactic fermentation | 1 | 802.5× | 0.011 | TP53 |
| regulation of osteoblast proliferation | 1 | 802.5× | 0.011 | FGFR2 |
| fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development | 1 | 802.5× | 0.011 | FGFR2 |
| response to L-leucine | 1 | 802.5× | 0.011 | PIK3CA |
| prostate epithelial cord elongation | 1 | 802.5× | 0.011 | FGFR2 |
Therapeutics
Drugs indicated for this disease
5 approved, 52 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Capecitabine | Approved (phase 4) |
| Docetaxel Anhydrous | Approved (phase 4) |
| Ramucirumab | Approved (phase 4) |
| Tislelizumab | Approved (phase 4) |
| Trastuzumab | Approved (phase 4) |
| Albumin Human | Phase 3 (in late-stage trials) |
| Ascorbic Acid | Phase 3 (in late-stage trials) |
| Aspirin | Phase 3 (in late-stage trials) |
| Avelumab | Phase 3 (in late-stage trials) |
| Bevacizumab | Phase 3 (in late-stage trials) |
| Camrelizumab | Phase 3 (in late-stage trials) |
| Catumaxomab | Phase 3 (in late-stage trials) |
| Cetuximab | Phase 3 (in late-stage trials) |
| Charcoal, Activated | Phase 3 (in late-stage trials) |
| Chlorambucil | Phase 3 (in late-stage trials) |
| Cisplatin | Phase 3 (in late-stage trials) |
| Clarithromycin | Phase 3 (in late-stage trials) |
| Dexmedetomidine | Phase 3 (in late-stage trials) |
| Doxifluridine | Phase 3 (in late-stage trials) |
| Endostatin, N-Terminal-Mggshhhhh | Phase 3 (in late-stage trials) |
| Epinephrine | Phase 3 (in late-stage trials) |
| Epirubicin | Phase 3 (in late-stage trials) |
| Etoposide | Phase 3 (in late-stage trials) |
| Everolimus | Phase 3 (in late-stage trials) |
| Fentanyl | Phase 3 (in late-stage trials) |
| Fluorouracil | Phase 3 (in late-stage trials) |
| Fruquintinib | Phase 3 (in late-stage trials) |
| G17DT IMMUNOGEN | Phase 3 (in late-stage trials) |
| Gimeracil | Phase 3 (in late-stage trials) |
| Ipilimumab | Phase 3 (in late-stage trials) |
| Irinotecan | Phase 3 (in late-stage trials) |
| Menthol | Phase 3 (in late-stage trials) |
| Mitomycin | Phase 3 (in late-stage trials) |
| Monosialotetrahexosylganglioside Sodium | Phase 3 (in late-stage trials) |
| Nefopam | Phase 3 (in late-stage trials) |
| Nivolumab | Phase 3 (in late-stage trials) |
| Olaparib | Phase 3 (in late-stage trials) |
| Omeprazole | Phase 3 (in late-stage trials) |
| Onartuzumab | Phase 3 (in late-stage trials) |
| Oteracil | Phase 3 (in late-stage trials) |
| Oxaliplatin | Phase 3 (in late-stage trials) |
| Paclitaxel | Phase 3 (in late-stage trials) |
| Pembrolizumab | Phase 3 (in late-stage trials) |
| Pemetrexed | Phase 3 (in late-stage trials) |
| Pertuzumab | Phase 3 (in late-stage trials) |
| Pucotenlimab | Phase 3 (in late-stage trials) |
| Ramosetron | Phase 3 (in late-stage trials) |
| Rilotumumab | Phase 3 (in late-stage trials) |
| Rivoceranib | Phase 3 (in late-stage trials) |
| Rofecoxib | Phase 3 (in late-stage trials) |
| Ropivacaine | Phase 3 (in late-stage trials) |
| Serplulimab | Phase 3 (in late-stage trials) |
| Simvastatin | Phase 3 (in late-stage trials) |
| Sintilimab | Phase 3 (in late-stage trials) |
| Tegafur | Phase 3 (in late-stage trials) |
| Tinidazole | Phase 3 (in late-stage trials) |
| Uracil | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Adebrelimab, Amivantamab, Atezolizumab, Bemarituzumab, Bortezomib, Cabazitaxel, Cadonilimab, Capivasertib, Carboplatin, Catequentinib, Cirmtuzumab, Crizotinib, Dexamethasone, Diphenhydramine, Disitamab Vedotin, Dovitinib, Doxorubicin, Durvalumab, Edotecarin, Eflornithine, Erythromycin, Famotidine, Filgrastim, Floxuridine, Ganetespib, Gefitinib, Hydroxyurea, Imatinib, Incomplete Freund’S Adjuvant, Interferon Alfa, Ipatasertib, Irofulven, Ixabepilone, KN-026, Lapatinib, Lenvatinib, Levoleucovorin, Linrodostat, Nimotuzumab, Onabotulinumtoxina, Palonosetron, Pamiparib, Panobinostat, Pazopanib, Pegfilgrastim, Pemigatinib, Penpulimab, Propranolol, Pyrotinib, Raltitrexed, Regorafenib, Relatlimab, Rilvegostomig, Rituximab, Romidepsin, Rucaparib, Sargramostim, Savolitinib, Sorafenib, Spartalizumab, Sunitinib, Taurine, Tipiracil, Tivantinib, Toripalimab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Tremelimumab, Tucatinib, Uridine Triacetate, Vandetanib, Vinflunine, Vismodegib, Volrustomig, Zanidatamab.
Drug target analysis
Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 3 · Undrugged: 4
Druggability breadth: 7 of 7 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Genes with an approved drug
The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.
| Symbol | Example approved molecule |
|---|---|
| TP53 | NITROFURANTOIN |
| FGFR2 | PONATINIB |
| PIK3CA | IDELALISIB |
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| TP53 | 196 | 4 |
| PIK3CA | 67 | 4 |
| FGFR2 | 59 | 4 |
| CASP10 | 0 | 0 |
| CDH1 | 0 | 0 |
| APC | 0 | 0 |
| MUTYH | 0 | 0 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| NITROFURANTOIN | 4 | TP53 |
| DIOSMIN | 4 | TP53 |
| VERTEPORFIN | 4 | TP53 |
| CANDESARTAN CILEXETIL | 4 | TP53 |
| DIENESTROL | 4 | TP53 |
| CLOTRIMAZOLE | 4 | TP53 |
| COLCHICINE | 4 | TP53 |
| NABUMETONE | 4 | TP53 |
| SALMETEROL XINAFOATE | 4 | TP53 |
| AMIODARONE HYDROCHLORIDE | 4 | TP53 |
| FURAZOLIDONE | 4 | TP53 |
| AMOXAPINE | 4 | TP53 |
| RALOXIFENE HYDROCHLORIDE | 4 | TP53 |
| NICARDIPINE HYDROCHLORIDE | 4 | TP53 |
| SULCONAZOLE NITRATE | 4 | TP53 |
| PYRITHIONE ZINC | 4 | TP53 |
| LACTIC ACID | 4 | TP53 |
| OXYMETHOLONE | 4 | TP53 |
| CHLOROXINE | 4 | TP53 |
| PROPIOLACTONE | 4 | TP53 |
| CLOMIPRAMINE HYDROCHLORIDE | 4 | TP53 |
| PHENYL AMINOSALICYLATE | 4 | TP53 |
| THIORIDAZINE HYDROCHLORIDE | 4 | TP53 |
| AMITRIPTYLINE HYDROCHLORIDE | 4 | TP53 |
| ETHOPROPAZINE HYDROCHLORIDE | 4 | TP53 |
| MECHLORETHAMINE HYDROCHLORIDE | 4 | TP53 |
| ECONAZOLE NITRATE | 4 | TP53 |
| TRIFLUPROMAZINE HYDROCHLORIDE | 4 | TP53 |
| PROCHLORPERAZINE EDISYLATE | 4 | TP53 |
| DEQUALINIUM CHLORIDE | 4 | TP53 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 3.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| PIK3CA | 2,034 | Binding:2009, ADMET:19, Toxicity:4, Functional:2 |
| FGFR2 | 966 | Binding:940, Functional:22, ADMET:4 |
| TP53 | 869 | Binding:775, ADMET:83, Functional:10, Toxicity:1 |
| APC | 24 | Binding:24 |
| CASP10 | 22 | Binding:21, Functional:1 |
| CDH1 | 18 | Binding:18 |
| MUTYH | 1 | Functional:1 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| CASP10 | 3.4.22.63 | caspase-10 |
| FGFR2 | 2.7.10.1 | receptor protein-tyrosine kinase |
| PIK3CA | 2.7.1.137, 2.7.1.153, 2.7.11.1 | phosphatidylinositol 3-kinase, phosphatidylinositol-4,5-bisphosphate 3-kinase, non-specific serine/threonine protein kinase |
Cohort genes with high screening signal
≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.
| Symbol | ChEMBL assays |
|---|---|
| TP53 | 869 |
| FGFR2 | 966 |
| PIK3CA | 2,034 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Drug repurposing candidates
30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| NITROFURANTOIN | 4 | TP53 |
| DIOSMIN | 4 | TP53 |
| VERTEPORFIN | 4 | TP53 |
| CANDESARTAN CILEXETIL | 4 | TP53 |
| DIENESTROL | 4 | TP53 |
| CLOTRIMAZOLE | 4 | TP53 |
| COLCHICINE | 4 | TP53 |
| NABUMETONE | 4 | TP53 |
| SALMETEROL XINAFOATE | 4 | TP53 |
| AMIODARONE HYDROCHLORIDE | 4 | TP53 |
| FURAZOLIDONE | 4 | TP53 |
| AMOXAPINE | 4 | TP53 |
| RALOXIFENE HYDROCHLORIDE | 4 | TP53 |
| NICARDIPINE HYDROCHLORIDE | 4 | TP53 |
| SULCONAZOLE NITRATE | 4 | TP53 |
| PYRITHIONE ZINC | 4 | TP53 |
| LACTIC ACID | 4 | TP53 |
| OXYMETHOLONE | 4 | TP53 |
| CHLOROXINE | 4 | TP53 |
| PROPIOLACTONE | 4 | TP53 |
| CLOMIPRAMINE HYDROCHLORIDE | 4 | TP53 |
| PHENYL AMINOSALICYLATE | 4 | TP53 |
| THIORIDAZINE HYDROCHLORIDE | 4 | TP53 |
| AMITRIPTYLINE HYDROCHLORIDE | 4 | TP53 |
| ETHOPROPAZINE HYDROCHLORIDE | 4 | TP53 |
| MECHLORETHAMINE HYDROCHLORIDE | 4 | TP53 |
| ECONAZOLE NITRATE | 4 | TP53 |
| TRIFLUPROMAZINE HYDROCHLORIDE | 4 | TP53 |
| PROCHLORPERAZINE EDISYLATE | 4 | TP53 |
| DEQUALINIUM CHLORIDE | 4 | TP53 |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 3 | TP53, FGFR2, PIK3CA |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 1 | CASP10 |
| E | Difficult family or no structure, no drug | 3 | CDH1, APC, MUTYH |
Undrugged target profiles
4 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| CASP10 | 22 | — |
| CDH1 | 18 | — |
| APC | 24 | — |
| MUTYH | 1 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 365.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 173 |
| PHASE2 | 100 |
| PHASE3 | 32 |
| PHASE1 | 32 |
| PHASE1/PHASE2 | 13 |
| PHASE4 | 9 |
| PHASE2/PHASE3 | 6 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07312370 | PHASE4 | NOT_YET_RECRUITING | Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing |
| NCT01579071 | PHASE4 | COMPLETED | Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor |
| NCT01653171 | PHASE4 | COMPLETED | Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy |
| NCT01819961 | PHASE4 | UNKNOWN | Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery |
| NCT02235246 | PHASE4 | COMPLETED | The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study |
| NCT04269369 | PHASE4 | UNKNOWN | Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients |
| NCT05068180 | PHASE4 | UNKNOWN | Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients |
| NCT05645198 | PHASE4 | UNKNOWN | The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy |
| NCT05688020 | PHASE4 | UNKNOWN | Tranexamic Acid During Upper GI Endoscopic Resection Procedures |
| NCT03348150 | PHASE3 | ACTIVE_NOT_RECRUITING | Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. |
| NCT05152147 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers |
| NCT06028737 | PHASE2/PHASE3 | RECRUITING | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer |
| NCT06504732 | PHASE2/PHASE3 | RECRUITING | To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer |
| NCT06977061 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression |
| NCT07018661 | PHASE2/PHASE3 | RECRUITING | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer |
| NCT00036400 | PHASE3 | COMPLETED | Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery |
| NCT00112099 | PHASE3 | COMPLETED | GCSSG-SPNX: Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: JCOG0110 |
| NCT00144378 | PHASE3 | COMPLETED | Irinotecan Versus Only Best Supportive Care for Gastric Cancer |
| NCT00147147 | PHASE3 | COMPLETED | Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2) |
| NCT00149266 | PHASE3 | TERMINATED | Randomized Controlled Trial to Evaluate Surgical Approaches to Gastric Cancer Invading the Esophagus (JCOG9502) |
| NCT00149279 | PHASE3 | COMPLETED | A Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer |
| NCT00252161 | PHASE3 | COMPLETED | A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer |
| NCT00290966 | PHASE2/PHASE3 | COMPLETED | Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer |
| NCT00411229 | PHASE3 | COMPLETED | Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer |
| NCT00811447 | PHASE3 | COMPLETED | Taxotere New Indication - Gastric Cancer Treatment Registration Trial |
| NCT01510730 | PHASE3 | COMPLETED | Helicobacter Pylori Eradication After Endoscopic Resection of Gastric Tumors |
| NCT01609309 | PHASE3 | UNKNOWN | Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01) |
| NCT01697943 | PHASE3 | UNKNOWN | Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Quality of Life in Patients Undergoing Total Gastrectomy |
| NCT01911832 | PHASE3 | UNKNOWN | Impact of Gastric Tube Reconstruction Widths on Quality of Life for Esophagogastric Cancers |
| NCT02005809 | PHASE3 | UNKNOWN | Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm |
| NCT02289547 | PHASE3 | UNKNOWN | Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer |
| NCT02338518 | PHASE3 | UNKNOWN | Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients |
| NCT02845479 | PHASE3 | COMPLETED | The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I |
| NCT02934464 | PHASE3 | UNKNOWN | Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers |
| NCT03013010 | PHASE3 | COMPLETED | PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy |
| NCT03019588 | PHASE3 | TERMINATED | Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) |
| NCT03023436 | PHASE3 | UNKNOWN | Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis |
| NCT03061058 | PHASE3 | UNKNOWN | Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC |
| NCT03475615 | PHASE3 | UNKNOWN | A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites |
| NCT03615326 | PHASE3 | COMPLETED | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| IRINOTECAN | 4 | 8 |
| PEMBROLIZUMAB | 4 | 3 |
| FRUQUINTINIB | 4 | 2 |
| OCTREOTIDE | 4 | 2 |
| PEMETREXED | 4 | 2 |
| RAMUCIRUMAB | 4 | 2 |
| TRASTUZUMAB DERUXTECAN | 4 | 2 |
| ACETYLCYSTEINE | 4 | 1 |
| AMIVANTAMAB | 4 | 1 |
| CAPECITABINE | 4 | 1 |
| CATUMAXOMAB | 4 | 1 |
| DOCETAXEL | 4 | 1 |
| DOSTARLIMAB | 4 | 1 |
| EPINEPHRINE | 4 | 1 |
| EPIRUBICIN HYDROCHLORIDE | 4 | 1 |
| EPOETIN ALFA | 4 | 1 |
| FISH OIL TRIGLYCERIDES | 4 | 1 |
| FLUMAZENIL | 4 | 1 |
| FLUOROURACIL | 4 | 1 |
| IXABEPILONE | 4 | 1 |
| MAGNESIUM SULFATE | 4 | 1 |
| MITOMYCIN | 4 | 1 |
| NEFOPAM | 4 | 1 |
| OXALIPLATIN | 4 | 1 |
| PYRVINIUM | 4 | 1 |
| REGORAFENIB | 4 | 1 |
| SIMETHICONE | 4 | 1 |
| SUCRALFATE | 4 | 1 |
| SUNITINIB | 4 | 1 |
| TISLELIZUMAB | 4 | 1 |
Related Atlas pages
- Cohort genes: TP53, CDH1, FGFR2, APC, PIK3CA, CASP10, MUTYH
- Drugs: Irinotecan, Pembrolizumab, Fruquintinib, Octreotide, Pemetrexed, Ramucirumab, Trastuzumab Deruxtecan, Acetylcysteine, Amivantamab, Capecitabine, Catumaxomab, Docetaxel, Dostarlimab, Epinephrine, Epirubicin, Epoetin Alfa, Fish Oil Triglycerides, Flumazenil, Fluorouracil, Ixabepilone, Magnesium, Mitomycin, Nefopam, Oxaliplatin, Pyrvinium, Regorafenib, Simethicone, Sucralfate, Sunitinib, Tislelizumab